Stock analysts at Raymond James Financial, Inc. started coverage on shares of Vital Therapies Inc (NASDAQ:VTL) in a research note issued to investors on Thursday. The brokerage set an “outperform” rating and a $6.00 price target on the stock. Raymond James Financial, Inc.’s price target indicates a potential upside of 130.77% from the company’s current price.

VTL has been the subject of several other research reports. Zacks Investment Research cut shares of Vital Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, March 25th. BTIG Research reiterated a “hold” rating on shares of Vital Therapies in a research note on Friday, March 10th.

Vital Therapies (NASDAQ:VTL) traded down 8.77% during mid-day trading on Thursday, hitting $2.60. 171,211 shares of the stock were exchanged. Vital Therapies has a one year low of $2.55 and a one year high of $8.38. The company’s market cap is $109.74 million. The company has a 50-day moving average price of $3.67 and a 200-day moving average price of $4.56.

Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings data on Tuesday, May 9th. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. During the same quarter in the previous year, the business posted ($0.31) EPS. Analysts forecast that Vital Therapies will post ($1.80) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/05/18/vital-therapies-inc-vtl-now-covered-by-raymond-james-financial-inc.html.

In related news, Director Muneer A. Satter acquired 3,750,000 shares of Vital Therapies stock in a transaction that occurred on Monday, March 27th. The stock was purchased at an average price of $4.00 per share, for a total transaction of $15,000,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 29.88% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in VTL. SG Americas Securities LLC acquired a new position in Vital Therapies during the first quarter valued at $167,000. Goldman Sachs Group Inc. increased its position in Vital Therapies by 1.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock valued at $258,000 after buying an additional 1,157 shares during the period. Bank of New York Mellon Corp increased its position in Vital Therapies by 11.5% in the first quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock valued at $352,000 after buying an additional 9,120 shares during the period. Geode Capital Management LLC increased its position in Vital Therapies by 5.8% in the first quarter. Geode Capital Management LLC now owns 172,210 shares of the company’s stock valued at $688,000 after buying an additional 9,448 shares during the period. Finally, State Street Corp increased its position in Vital Therapies by 6.0% in the fourth quarter. State Street Corp now owns 328,091 shares of the company’s stock valued at $1,427,000 after buying an additional 18,645 shares during the period. Hedge funds and other institutional investors own 26.68% of the company’s stock.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

5 Day Chart for NASDAQ:VTL

Receive News & Ratings for Vital Therapies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc and related companies with MarketBeat.com's FREE daily email newsletter.